Lv1
30 积分 2024-03-05 加入
Impact of Premedication De-Escalation on Incidence of Infusion-Related Reactions With Daratumumab
1个月前
已完结
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
6个月前
已完结
Real‐World Data Analysis on Early Mortality in Chinese Multiple Myeloma Patients: Analysis of 1093 Patients During a 15‐Year Period
6个月前
已完结
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
6个月前
已完结
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
6个月前
已完结
Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study
7个月前
已完结
Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study
7个月前
已完结
Comprehensive Next-Generation Sequencing Testing in a Patient with TEMPI Syndrome
7个月前
已完结
皖公网安备34019202002308
